| FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Issuer Name and Ticker or Trading Symbol XYNOMIC PHARMACEUTICALS HOLDINGS, INC. [ XYN ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| ||||||||||||||||||||||||
| 3. Date of Earliest Transaction (Month/Day/Year) 05/15/2019 | ||||||||||||||||||||||||||
| 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock, par value $0.0001 per share | 05/15/2019 | P(1) | 108,980(1) | A | (1) | 1,628,580 | I | See Footnote(3) | ||
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Warrants | $11.5 | 05/15/2019 | P(1) | 25,000 | 05/15/2019 | 05/15/2024 | Common Stock | 25,000(2) | $11.5(1) | 225,937 | I | See Footnote(3) | |||
| Explanation of Responses: |
| 1. In connection with the closing of a business combination with Xynomic Pharmaceuticals, Inc. (the "Closing"), Bison Capital Holding Company Limited, a Cayman Islands company ("Bison Capital"), (A) purchased 13,793 shares (the "Backstop Shares") of common stock of Bison Capital Acquisition Corp., a Delaware corporation (now known as Xynomic Pharmaceuticals Holdings, Inc., the "Company"), par value $0.001 per share pursuant to a Backstop and Subscription Agreement dated May 1, 2019 between the Company and Yiling Mark Xu; (B) converted its $500,000 promissory notes issued by the Company into 55,000 common shares and 25,000 warrants, each exercisable to purchase one share of common stock at $11.50 per whole share; and (C) received 40,187 common shares upon the exchange of its rights immediately outstanding prior to the Closing. |
| 2. Pursuant to the promissory note and warrant agreement, each unit consists of one share; each whole warrant entitles the holder to one common share exercisable at $11.50 per share, expiring at the 5th anniversary of the Closing. |
| 3. Fengyun Jiang, who has 100% ownership interest in Bison Capital and is Peixin Xu's spouse, has voting and dispositive power over the shares held by such entity. Mr. Xu was the Chairman of the Company but resigned at the closing of a business combination, effective May 15, 2019. |
| /s/ Peixin Xu | 05/21/2019 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
